Published in Physician Law Weekly, September 1st, 2004
Total revenue increased 53% to $18.9 million in the second quarter of 2004 compared to $12.3 million for the same quarter in 2003. The revenue increase was due primarily to $9.9 million in sales and royalty revenue earned from the continued growth of the Eligard (leuprolide acetate for injectable suspension) prostate cancer products.
This represents a 42% increase in Eligard sales and royalty revenue compared to the first quarter of 2004.
Operating expenses in the second quarter of 2004 increased to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.